UTD1 is currently an alternative for the treatment of metastatic breast cancer (MBC), especially in breast cancer previously treated with anthracyclines and taxanes [108], as well as for patients with HER2-positive breast cancer [109]. This evidence concerns the gene ERBB2 and breast carcinoma.